InventisBio (SHA:688382) submitted documents for its planned share offering on the Hong Kong Stock Exchange, according to a Monday disclosure to the Shanghai bourse.
The biopharmaceutical company intends to use the proceeds from its planned share offering for research and development of its core products and antibody-drug conjugates, and for working capital, according to an application proof submitted to the Hong Kong bourse Jan. 1.
Shares rose 1% in Shanghai during morning trading on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments